The Role of Adrenomedullin on the Outcome of Severe Heart Failure: a Clinical Randomized Study

Study Overview
=================
Brief Summary
-----------------
Study Hypothesis: The decrease of plasma adrenomedullin (ADM) concentration by ultrafiltration and isovolumetric hemofiltration in patients with acute III and IV Class New York Heart Association Functional(NYHA) heart failure is more pronounced than a standard diuretic treatment and is related with clinical improvement. Outcome Measurements: To correlate the adrenomedullin plasma levels with clinical treatment, ultrafiltration and hemofiltration related to: Brain natriuretic peptide (BNP) level angiotensin II level sympathetic nervous activity oxydative stress clinical outcome at the beginning, at discharge and 90 days after randomization.

Detailed Description
-----------------
Testing the hypothesis that adrenomedullin (ADM) is a important peptide in severe heart failure and that is related to clinical condition, we will study the effects of 3 different treatments (clinical usual treatment,ultrafiltration and isovolumetric hemofiltration with diuretics) to participants are followed until discharge to Adrenomedullin level and clinical outcomes,and also their relationship with angiotensin II level, brain natriuretic peptide(BNP), sympathetic nervous system and oxydative stress. The patients will be randomized in three different treatment group and analyzed in three moments: on the randomization, at discharge and 90 days after randomization(plus or minus 3). The clinical treatment will be optimized, the ultrafiltration will be done until clinically adequate fluid removal or until hematocrit increased 10% from basal level, and isovolumetric hemofiltration will be done for 8 hours- dose of 35 ml/kg/h in association with diuretic. All this dialytic procedures will be done with PAES membrane- filter HF1400 and automatic machine.

Official Title
-----------------
The Role of Adrenomedullin on the Outcome of Severe Heart Failure: a Clinical Randomized Study

Conditions
-----------------
Heart Failure

Intervention / Treatment
-----------------
* Other: clinical treatment
* Procedure: ultrafiltration
* Procedure: isovolumetric hemofiltration


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: more than two item: more than eighteen years of age orthopnea Chest Rx with cardiomegaly and pulmonary infiltration edema diuretic resistance Exclusion Criteria: insulin dependent diabetes hepatic cirrhosis vascular access problems creatinine more than 2,5 mg/dl before acute heart failure systemic infection aortic stenosis and heart transplantation radiologic contrast up to 72 hours prior randomization advanced neoplasia

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: clinical treatment<br>Patients with previous diagnosis of decompensated III and IV Heart Failure will be included. The clinical treatment will be optimized. Clinical assessment, Adrenomedullin, Angiotensin II, Brain Natriuretic Peptide, oxydative stress, sympathetic nervous system activity will be evaluated at the beginning, at discharge and 90 days after randomization(plus or minus3). | Other: clinical treatment<br>* The clinical treatment will be optimized to gold standard international heart failure treatment<br>* Other names: adrenomedullin;|
| Experimental: ultrafiltration<br>ultrafiltration will be done on decompensated patients III and IV acute heart failure on Intensive Care Unit. This patients will have biochemical analysis, adrenomedullin, angiotensin II,Brain Natriuretic Peptide, oxydative stress measurements,sympathetic nervous system activity evaluated and clinical outcome analyzed at the beginning,at discharge and 90 days after randomization(plus or minus 3). Diuretic will be withdrawn during ultrafiltration. | Procedure: ultrafiltration<br>* The ultrafiltration procedure will be done on Intensive Care Unit with automatic machine and HF 1400 filter. The fluid will be removed until a increased of 10% in hematocrit or clinical improvement.<br>* Other names: adrenomedullin;|
| Experimental: isovolumetric hemofiltration<br>Patients randomized to this group will have isovolumetric hemofiltration on Intensive Care Unit. They will have biochemical analysis, Adrenomedullin plasmatic level, Brain Natriuretic Peptide Level, Angiotensin II level, Oxydative stress measurement,sympathetic nervous system, and clinical outcome evaluated at the study beginning,at discharge and 90 days after randomization(plus or minus 3). | Procedure: isovolumetric hemofiltration<br>* The isovolumetric hemofiltration will be done in Intensive Care Unit for 8 hours, and will be permitted the diuretic use.The dose will be 35 ml/kg/hour and will e used automatic machine and MF1400 filter.Diuretic use will be maintained.<br>* Other names: adrenomedullin;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Levels of Adrenomedullin plasma in different treatments- clinical,ultrafiltration and isovolumetric hemofiltration | The adrenomedullin level will be compared in three different treatments: clinical treatment, ultrafiltration treatment and isovolumetric hemofiltration. | 90 days after randomization (plus or minus 3 days). | 
| Levels of Adrenomedullin plasma in different treatments- clinical,ultrafiltration and isovolumetric hemofiltration | The adrenomedullin level will be compared in three different treatments: clinical treatment, ultrafiltration treatment and isovolumetric hemofiltration. The patients will be followed until discharge. | at discharge | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The Adrenomedullin plasma levels in three different treatment approaches will be related to clinical outcome. | The correlation of adrenomedullin plasma levels in all 3 arms related to optimized clinical outcome. The patients will be followed until discharge | at discharge | 
| The Adrenomedullin plasma levels in three different treatment approaches will be related to clinical outcome. | The correlation of adrenomedullin plasma levels in all 3 arms related to optimized clinical outcome. | 90 days after randomization (plus or minus 3) | 
| The Adrenomedullin plasma levels in three different treatment approaches will be related to oxydative stress | The correlation of adrenomedullin plasma levels in all 3 arms related to oxydative stress. The patients will be followed until discharge. | at discharge | 
| The Adrenomedullin plasma levels in three different treatment approaches will be related to oxydative stress | The correlation of adrenomedullin plasma levels in all 3 arms related to oxydative stress. | 90 days after randomization(plus or minus 3) | 
| The Adrenomedullin plasma levels in three different treatment approaches will be related to angiotensin II plasma level | The correlation of adrenomedullin plasma levels in all 3 arms related to angiotensin II level. The patients will be followed until discharge. | at discharge | 
| The Adrenomedullin plasma levels in three different treatment approaches will be related to angiotensin II plasma level | The correlation of adrenomedullin plasma levels in all 3 arms related to angiotensin II plasma level. | 90 days after randomization(plus or minus 3) | 
| The Adrenomedullin plasma levels in three different treatment approaches will be related to Brain natriuretic peptide plasma level | The correlation of adrenomedullin plasma levels in all 3 arms related to Brain natriuretic peptide level. The patients will be followed until discharge. | at discharge | 
| The Adrenomedullin plasma levels in three different treatment approaches will be related to Pro-Brain natriuretic peptide plasma level | The correlation of adrenomedullin plasma levels in all 3 arms related to Brain natriuretic peptide level, 90 days after randomization(plus or minus 3) | 90 days after randomization(plus or minus 3) | 
| The Adrenomedullin plasma levels in three different treatment approaches will be related to sympathetic nervous system activity | The correlation of adrenomedullin plasma levels in all 3 arms related to sympathetic nervous system.The patients will be followed until discharge. | at discharge | 
| The Adrenomedullin plasma levels in three different treatment approaches will be related to sympathetic nervous system activity | The correlation of adrenomedullin plasma levels in all 3 arms related to sympathetic nervous system. | 90 days after randomization(plus or minus 3) | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
adrenomedullin, heart failure, ultrafiltration, hemofiltration